NLRC4 and metabolic dysfunction-associated steatohepatitis: NLRC4 knockdown inhibited PA‐induced inflammation and lipid accumulation, therefore presenting DHA as a potential antagonist for NLRC4 to provide beneficial hepatoprotective effects in NASH [18].